arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

LENZ Therapeutics, Inc.

LENZ

$5.37 ▲ +0.15 (+2.78%) at close

7 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

LENZ Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $154.7M

Dividend Yield —

Revenue Growth —

Op. Margin -477.5%

ROIC -32.2% ↘

FCF / Share $-2.43 ↗

Trailing P/E —

Price / Book 0.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$19.09M

— —

Net Income Profit after all expenses

$-82.13M

↓ -65.0% —

FCF / Share Free cash flow per share

$-2.43

↑ +13.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability

Returns ↓

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	-21.8% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	93.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-1840.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	24.9% Good Good Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-65.0% Weak ↓ Weak Declining Year-over-year change in net income	28.9% Excellent ↑ Excellent Improving Year-over-year change in net income	30.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-42.8% Weak Weak Year-over-year change in net income	-3.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	13.6% Fair ↑ Fair Improving Year-over-year change in free cash flow	90.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-1689.1% Weak Weak Year-over-year change in free cash flow	14.9% Fair Fair Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	-477.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3283%)	—	—	—	—	—	—
Effective Tax Rate (%) (%)	-0.6% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—
Profit Margin (%) (%)	-430.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3685%)	—	—	—	—	—	—
FCF Margin (%) (%)	-366.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—
FCF / Net Income (x)	0.85x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.20x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.15x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-32.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-28.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	77.9% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-28.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	16.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-29.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-27.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-102.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-15.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-59.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-28.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-293%)	-24.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-263%)	75.5% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+403%)	-34.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-327%)	-18.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-223%)	104.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+597%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-25.18M	$-20.16M	$-35.14M	$-47.73M	$-376.98M	$-19.78M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.66	$0.00	—	—	—	—	—
Basic EPS, GAAP (USD)	$-2.85	$-2.34	$-35.71	$-1.84	$-2.45	—	—
Free Cash Flow per Share (USD)	$-2.43	$-2.81	$-30.84	$-1.72	$-2.03	—	—
Book Value per Share (USD)	$9.07	$7.42	$-47.08	$5.09	$6.62	$-6.36	—
Tangible Book Value per Share (USD)	$9.07	$7.42	$-47.08	$5.09	$6.62	$-6.36	—
Basic Weighted Avg Shares (shares)	28.81M	21.28M	1.96M	54.87M	28.92M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$280.23M	$201.51M	$48.73M	$262.32M	$369.59M	$-10.95M	—
Total Equity (USD)	$284.34M	$204.08M	$-92.71M	$296.29M	$384.05M	$-65.41M	$-2.22M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$19.09M	$0.00	—	—	—	—	—
Depreciation Expense (USD)	$287.00K	$58.00K	$15.00K	$2.40M	—	$100.00K	—
Net Income, GAAP (USD)	$-82.13M	$-49.77M	$-69.97M	$-101.05M	$-70.76M	$-68.37M	—
Operating Cash Flow (USD)	$-69.17M	$-59.39M	$-60.38M	$-87.98M	$-52.85M	$-8.72M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

LENZ Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare LENZ with peers